DE69429337T2 - Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel - Google Patents

Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel

Info

Publication number
DE69429337T2
DE69429337T2 DE69429337T DE69429337T DE69429337T2 DE 69429337 T2 DE69429337 T2 DE 69429337T2 DE 69429337 T DE69429337 T DE 69429337T DE 69429337 T DE69429337 T DE 69429337T DE 69429337 T2 DE69429337 T2 DE 69429337T2
Authority
DE
Germany
Prior art keywords
hair
liposomes
encapsulating
delivery
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69429337T
Other languages
English (en)
Other versions
DE69429337T3 (de
DE69429337D1 (de
Inventor
Lingna Li
Valeryi K Lishko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anticancer Inc
Original Assignee
Anticancer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26718278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69429337(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/181,471 external-priority patent/US5641508A/en
Application filed by Anticancer Inc filed Critical Anticancer Inc
Application granted granted Critical
Publication of DE69429337D1 publication Critical patent/DE69429337D1/de
Publication of DE69429337T2 publication Critical patent/DE69429337T2/de
Publication of DE69429337T3 publication Critical patent/DE69429337T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y110/00—Oxidoreductases acting on diphenols and related substances as donors (1.10)
    • C12Y110/03—Oxidoreductases acting on diphenols and related substances as donors (1.10) with an oxygen as acceptor (1.10.3)
    • C12Y110/03001—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/10—Preparations for permanently dyeing the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/18—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with another compound as one donor, and incorporation of one atom of oxygen (1.14.18)
    • C12Y114/18001—Tyrosinase (1.14.18.1)
DE69429337T 1993-04-02 1994-04-01 Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel Expired - Lifetime DE69429337T3 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US41553 1987-04-22
US4155393A 1993-04-02 1993-04-02
US08/181,471 US5641508A (en) 1994-01-13 1994-01-13 Method for delivering melanin to hair follicles
US181471 1994-01-13
PCT/US1994/003634 WO1994022468A1 (en) 1993-04-02 1994-04-01 Method for delivering beneficial compositions to hair follicles
EP94913349A EP0692972B2 (de) 1993-04-02 1994-04-01 Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel

Publications (3)

Publication Number Publication Date
DE69429337D1 DE69429337D1 (de) 2002-01-17
DE69429337T2 true DE69429337T2 (de) 2002-10-10
DE69429337T3 DE69429337T3 (de) 2012-08-30

Family

ID=26718278

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69429337T Expired - Lifetime DE69429337T3 (de) 1993-04-02 1994-04-01 Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel

Country Status (8)

Country Link
US (5) US5753263A (de)
EP (1) EP0692972B2 (de)
JP (1) JP2950520B2 (de)
AT (1) ATE209887T1 (de)
AU (1) AU6554594A (de)
CA (1) CA2159626C (de)
DE (1) DE69429337T3 (de)
WO (1) WO1994022468A1 (de)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7556825B2 (en) * 1993-04-02 2009-07-07 Anticancer, Inc. Method for promoting hair growth
ATE209887T1 (de) * 1993-04-02 2001-12-15 Anticancer Inc Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5480901A (en) * 1994-10-07 1996-01-02 Zynaxis, Inc. Method for reducing unwanted cellular adhesions
US6844326B2 (en) * 1995-06-07 2005-01-18 Anticancer, Inc. Treatment of alopecia
US5756122A (en) * 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
US6261597B1 (en) * 1995-08-31 2001-07-17 Seymour J. Kurtz Method for treating periodontal disease
US6459805B1 (en) * 1996-03-26 2002-10-01 Childrens Hospital Los Angeles Fluorescence digital imaging microscopy system
US5766214A (en) * 1996-04-18 1998-06-16 Mehl, Sr.; Thomas L. Melanin enhanced photothermolysis hair removal
WO1997046671A1 (en) * 1996-05-30 1997-12-11 University Of British Columbia Enhanced efficacy of liposomal antisense delivery
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US6835393B2 (en) * 1998-01-05 2004-12-28 University Of Washington Enhanced transport using membrane disruptive agents
US6348348B1 (en) * 1998-04-07 2002-02-19 The Carnegie Institution Of Washington Human hairless gene and protein
JP2002515514A (ja) * 1998-05-21 2002-05-28 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの局所送逹のための組成物及び方法
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
DE69928960T2 (de) * 1998-10-27 2006-08-10 Anticancer Inc., San Diego Herstellung eines retrovirus, welches den mel-lokus von streptomyces enthält, sowie dessen expression in säugetierzellen
US6372489B1 (en) 1998-10-27 2002-04-16 Anticancer, Inc. Method and model for hair pigmentation
FR2791671B1 (fr) 1999-04-01 2001-05-11 Oreal Nouveaux composes derives d'esters d'acide benzoique, composition les comprenant et utilisation
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
GB9918670D0 (en) * 1999-08-06 1999-10-13 Celltech Therapeutics Ltd Biological product
KR20020020274A (ko) 1999-08-18 2002-03-14 히라타 다다시 육모제
EP1096255B1 (de) * 1999-10-29 2008-09-17 Shiseido Company Limited Verfahren zur Messung von Hautabsorption
EP1237582B1 (de) * 1999-12-10 2011-09-14 AntiCancer, Inc. Verfahren zur einführung von genen in säugetiere
WO2001051092A2 (en) 2000-01-07 2001-07-19 University Of Washington Enhanced transport of agents using membrane disruptive agents
US20030017183A1 (en) * 2000-01-11 2003-01-23 Pollock David E. Dermatological suspensions(micro-matrix)
CA2408152A1 (en) * 2000-05-05 2001-11-15 Wisconsin Alumni Research Foundation Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
US20040022838A1 (en) * 2001-06-20 2004-02-05 Holick Michael F. Regulation of cell proliferation and differentiation using topically applied peptides
CA2413860A1 (en) * 2000-06-22 2001-12-27 Michael F. Holick Regulation of cellproliferation and differentiation using topically applied peptides
WO2002007674A2 (en) * 2000-07-21 2002-01-31 Ceramoptec Industries, Inc. Enhancing compound penetration into hair follicles
AU2001296585A1 (en) * 2000-10-06 2002-04-15 Michael F. Holick Regulation of cell proliferation and differentiation using topically applied nucleic acid molecules
DE10109897A1 (de) * 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
US20020192738A1 (en) * 2001-04-27 2002-12-19 Janice Brissette Tyrosinase assay
US7923431B2 (en) * 2001-12-21 2011-04-12 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
US7858117B2 (en) * 2002-02-21 2010-12-28 Novosom Ag Amphoteric liposomes and their use
WO2003083443A2 (en) * 2002-03-29 2003-10-09 University Of Florida Lipid mediated screening of drug candidates for identification of active compounds
EP1352631A1 (de) * 2002-04-08 2003-10-15 Kao Corporation Haarfärbemittel
FR2840531B1 (fr) * 2002-06-11 2004-10-29 Oreal Composition cosmetique comprenant un agent mimetique de l'activite de la dopachrome tautomerase (trp-2) pour lutter contre la canitie
AU2003255653A1 (en) * 2002-06-11 2003-12-22 L'oreal Use of an agent mimicking dopachrome tautomerase (trp-2) activity as protective agent for hair follicle melanocytes and uses thereof
US7585514B2 (en) * 2002-06-11 2009-09-08 L'oreal Administration of agents mimicking DOPAchrome tautomerase (TRP-2) activity for protecting hair follicle melanocytes
FR2840530B1 (fr) * 2002-06-11 2004-12-24 Oreal Composition cosmetique comprenant un agent inducteur de l'expression de la dopachrome tautomerase (trp-2) pour lutter contre la canitie
WO2004026249A2 (en) * 2002-09-20 2004-04-01 The General Hospital Corporation Methods and compositions for preventing skin damage
MXPA05006193A (es) * 2002-12-11 2005-12-05 Ferrosan As Materiales basados en gelatina como hisopos.
WO2004073594A2 (fr) * 2003-02-12 2004-09-02 L'oreal Utilisation d’un inhibiteur de 15-hydroxy prostaglandine deshydrogenase pour favoriser la pigmentation de la peau ou des phaneres
FR2850864B1 (fr) * 2003-02-12 2007-04-13 Oreal Utilisation d'un inhibiteur de 15-hydroxy prostaglandine deshydrogenase pour favoriser la pigmentation de la peau ou des phaneres
US7326717B2 (en) 2003-05-06 2008-02-05 L'oreal Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
AU2004247013B2 (en) * 2003-05-14 2010-07-08 Neurogenetic Pharmaceuticals, Inc. Compounds and uses thereof in modulating amyloid beta
DE10340373A1 (de) * 2003-08-30 2005-03-24 Henkel Kgaa Verfahren zur Bestimmung von Haarzyklus-Marken
US20050058614A1 (en) * 2003-09-15 2005-03-17 Allergan, Inc. Methods for the treatment of gray hair using cyclopentane(ene) heptan(en)oic acid amides
WO2005046584A2 (en) 2003-11-05 2005-05-26 Osteoscreen, Inc. Stimulation of hair growth by ginkgo biloba flavanoids
US7867511B2 (en) * 2004-01-23 2011-01-11 Travanti Pharma Inc. Abuse potential reduction in abusable substance dosage form
US8535711B2 (en) * 2004-01-23 2013-09-17 Teikoku Pharma Usa, Inc. Medication disposal system
JP2007519450A (ja) * 2004-01-30 2007-07-19 フェロサン アー／エス 止血用のスプレーおよび組成物
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
US8168600B2 (en) * 2004-04-23 2012-05-01 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
WO2005105157A2 (en) * 2004-04-23 2005-11-10 The Trustees Of Columbia University In The City Ofnew York INHIBITION OF HAIRLESS PROTEIN mRNA
US7706873B2 (en) 2004-05-05 2010-04-27 Mario Ammirati System and method for controlled delivery of a therapeutic agent to a target location within an internal body tissue
DE102004028465A1 (de) * 2004-06-11 2005-12-29 Henkel Kgaa Färbemittel für keratinhaltige Fasern
CA2571981C (en) * 2004-07-09 2014-12-30 Ferrosan A/S Haemostatic composition comprising hyaluronic acid
US20060073117A1 (en) * 2004-10-01 2006-04-06 Stowers Institute For Medical Research Methods and compositions for controlling hair follicle stem cell fate
US7964571B2 (en) 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
JP2008531581A (ja) * 2005-02-23 2008-08-14 ユーエービー リサーチ ファウンデーション アルキル−グリコシドで増強されたワクチン接種
JP2008534494A (ja) * 2005-03-24 2008-08-28 メディジーンズ カンパニー リミテッド 脱毛治療または毛髪成長促進用の組成物
WO2006128084A2 (en) * 2005-05-27 2006-11-30 The Trustees Of Columbia University In The City Of New York Trps1-mediated modulation of hair growth
AU2006291429B2 (en) * 2005-09-15 2013-04-04 Biontech Delivery Technologies Gmbh Improvements in or relating to amphoteric liposomes
WO2007109584A1 (en) * 2006-03-16 2007-09-27 University Of Washington Temperature-and ph-responsive polymer compositions
US20080193514A1 (en) * 2006-11-02 2008-08-14 Transcu Ltd. Compostions and methods for iontophoresis delivery of active ingredients through hair follicles
DE102006060154A1 (de) * 2006-12-18 2008-06-19 Henkel Kgaa Verfahren zur molekularen Charakterisierung von ergrautem und pigmentiertem Haar
US7981688B2 (en) 2007-03-08 2011-07-19 University Of Washington Stimuli-responsive magnetic nanoparticles and related methods
EP3091075B1 (de) 2007-04-09 2018-06-13 The Board of Trustees of The University of Arkansas Fusionsproteine von kollagenbindender domäne und parathyroidhormon
FR2918885B1 (fr) 2007-07-17 2009-08-28 Oreal Utilisation d'extrait de bacterie cultivee sur eau thermale pour diminuer les poches et/ou les cernes perioculaires
US9144546B2 (en) 2007-08-06 2015-09-29 Clsn Laboratories, Inc. Nucleic acid-lipopolymer compositions
FR2920309B1 (fr) 2007-08-28 2010-05-28 Galderma Res & Dev Utilisation de travoprost pour traiter la chute des cheveux
US7737125B2 (en) 2007-11-26 2010-06-15 Enzon Pharamaceuticals, Inc. LNA antagonists targeting the androgen receptor
CN102014973A (zh) * 2008-02-29 2011-04-13 弗罗桑医疗设备公司 用于促进止血和/或伤口愈合的装置
FR2928545B1 (fr) * 2008-03-17 2013-08-02 Oreal Utilisation d'inhibiteurs de monoamines oxydases pour la pigmentation capillaire
FR2928546B1 (fr) * 2008-03-17 2013-08-02 Oreal Utilisation d'inhibiteurs de la dopa decarboxylase pour la pigmentation capillaire.
FR2928543B1 (fr) * 2008-03-17 2013-08-02 Oreal Utilisation d'inhibiteurs de la xanthine oxydase pour la pigmentation capillaire
FR2928544A1 (fr) * 2008-03-17 2009-09-18 Oreal Utilisation d'inhibiteurs de la dopamine-beta hydroxylase pour la pigmentation capillaire.
FR2929118B1 (fr) 2008-03-28 2010-05-07 Oreal Utilisation de l'association de madecassoside et/ou de terminoloside et d'une arginine pour induire et/ou stimuler la croissance de ces fibres keratiniques humaines et/ou freiner leur chute
FR2929117B1 (fr) 2008-03-28 2010-05-07 Oreal Utilisation de l'association du 2,4-diaminopyrimidine 3-n-oxyde et du madecassosside et/ou du terminoloside pour induire et/ou stimuler la croissance de ces fibres keratiniques humaines et/ou freiner leur chute
US8426214B2 (en) * 2009-06-12 2013-04-23 University Of Washington System and method for magnetically concentrating and detecting biomarkers
US9080933B2 (en) 2009-11-09 2015-07-14 University Of Washington Through Its Center For Commercialization Stimuli-responsive polymer diagnostic assay comprising magnetic nanoparticles and capture conjugates
US20110117668A1 (en) * 2009-11-09 2011-05-19 University Of Washington Through Its Center For Commercialization Self-powered smart diagnostic devices
WO2012065051A1 (en) 2010-11-12 2012-05-18 Enzon Pharmaceuticals, Inc. Compositions and methods for treating androgen receptor dependent disorders including cancers
CA2834365A1 (en) 2011-04-28 2012-11-01 Sandia Corporation Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
CA2842306A1 (en) * 2011-07-19 2013-01-24 Stc.Unm Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers
BR112014005543A2 (pt) 2011-09-30 2017-03-21 Teikoku Pharma Usa Inc sistema de descarte de medicação geral
JP5964435B2 (ja) 2011-09-30 2016-08-03 テイコク ファーマ ユーエスエー インコーポレーテッド 経皮パッチ廃棄システム
EP3391899B1 (de) * 2011-12-14 2020-07-15 The Board of Trustees of the University of Arkansas Abgabe therapeutischer wirkstoffe über ein kollagenbindungsprotein
EP2805713B1 (de) 2012-01-18 2018-10-10 Bioneer Corporation Samirna-komplex mit magnetischen nanopartikeln und verfahren zur herstellung davon
US9526765B2 (en) 2012-02-09 2016-12-27 The Kitasato Institute Delivery of therapeutic agents by a collagen binding protein
EP2822474B1 (de) 2012-03-06 2018-05-02 Ferrosan Medical Devices A/S Druckbehälter mit einer blutstillenden paste
BR112014030962A2 (pt) 2012-06-12 2017-06-27 Ferrosan Medical Devices As métodos para preparação e para reconstituição de uma composição seca adequada para uso em hemostase e cicatrização de feridas, e, kit hemostático
CN104428037B (zh) * 2012-07-10 2017-09-08 皇家飞利浦有限公司 通过选择性加热毛发从容器中的分子释放
EP2877573B1 (de) * 2012-07-26 2016-09-21 Unilever N.V. Verfahren zur herstellung rekombinanter menschlicher tyrosinase
EP3696276A1 (de) 2013-02-25 2020-08-19 Novartis AG Neuartige androgenrezeptormutation
US9724078B2 (en) 2013-06-21 2017-08-08 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
US9695421B2 (en) 2013-07-05 2017-07-04 Bioneer Corporation Dengue virus-specific siRNA, double helix oligo-RNA structure comprising siRNA, and composition for suppressing proliferation of dengue virus comprising RNA structure
EP3018208B1 (de) 2013-07-05 2020-05-27 Bioneer Corporation Verbesserte oligonukleotid-nanopartikel struktur mit hoher effizienz und verfahren zur herstellung davon
KR20150006742A (ko) * 2013-07-09 2015-01-19 (주)바이오니아 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물
EP3470094B1 (de) 2013-12-11 2020-07-22 Ferrosan Medical Devices A/S Trockenzusammensetzung mit extrusionsverstärker
BR112016023004B1 (pt) 2014-04-04 2023-12-05 Bioneer Corporation Sirna, estrutura oligo rna de fita dupla, nanopartícula, composição farmacêutica e estrutura liofilizada para prevenir ou tratar fibrose ou doenças respiratórias contendo a mesma
WO2016058612A1 (en) 2014-10-13 2016-04-21 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
WO2016102446A1 (en) 2014-12-24 2016-06-30 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
WO2017005590A1 (en) 2015-07-03 2017-01-12 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
US11624060B2 (en) 2017-02-10 2023-04-11 The Board Of Trustees Of The University Of Arkansas Collagen-binding agent compositions and methods of using the same
US11389844B2 (en) 2018-03-20 2022-07-19 Verde Environmental Technologies, Inc. Blister pack disposal system
EP4321182A2 (de) 2018-05-09 2024-02-14 Ferrosan Medical Devices A/S Verfahren zur herstellung einer hämostatischen zusammensetzung
CN112245571A (zh) * 2020-09-16 2021-01-22 陕西中鸿科瑞再生医学研究院有限公司 一种用于乌发的脂质体制剂及其制备方法
US20230000746A1 (en) * 2021-06-30 2023-01-05 Abe Pharmaceutical Composition for stimulating facial hair growth and methods of manufacturing a composition for stimulating facial hair growth

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5147778B2 (de) 1973-12-01 1976-12-16
US4925661A (en) * 1984-04-19 1990-05-15 Leaf Huang Target-specific cytotoxic liposomes
US4957735A (en) * 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US4755388A (en) * 1984-11-09 1988-07-05 The Regents Of The University Of California Liposome-encapsulated 5-fluoropyrimidines and methods for their use
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
GB8604360D0 (en) * 1986-02-21 1986-03-26 Univ Dundee Stimulation of hair growth
US4806344A (en) 1987-01-05 1989-02-21 Gaskin Frances C Sun protectant composition and method
US4828837A (en) * 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
US5290562A (en) * 1987-11-27 1994-03-01 L V M H Recherche Compositions and methods employing liposomes including tyrosine or a tyrosine derivative
FR2628317B1 (fr) * 1988-03-09 1991-11-08 Lvmh Rech Composition a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un extrait de scutellaria, ou au moins un flavonoide tel que baicaleine ou baicaline et composition cosmetique ou pharmaceutique, notamment dermatologique, a activite anti-allergique, anti-inflammatoire ou anti-vieillissement, l'incorporant
US5077211A (en) * 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5190762A (en) * 1988-07-06 1993-03-02 Applied Genetics, Inc. Method of administering proteins to living skin cells
US5210076A (en) * 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
IT1231260B (it) * 1988-11-16 1991-11-28 Sergio Bertini Curri Farmaco e metodo per aumentare volume e velocita' del flusso microcircolatorio capillare a livello cutaneo
US5618798A (en) * 1989-04-20 1997-04-08 Bar-Shalom; Daniel Use of sucralfate to treat baldness
FR2648132B1 (fr) * 1989-06-08 1991-09-13 Thorel Jean Composes pigmentogenes, leurs vehicules de diffusion, compositions les contenant et leur procede de preparation
FR2654935B1 (fr) * 1989-11-28 1994-07-01 Lvmh Rech Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux.
GB9014221D0 (en) * 1990-06-26 1990-08-15 Janssen Pharmaceutica Nv Method of treating alopecia
FR2669225B1 (fr) * 1990-11-21 1993-11-12 Lvmh Recherche Gie Utilisation de saponines de medicago pour la preparation de compositions cosmetiques ou pharmaceutiques, notamment dermatologiques.
US5723149A (en) * 1990-11-21 1998-03-03 Lvmh Recherche Use of medicago saponins for the preparation of cosmetic or pharmaceutical compositions, especially dermatological compositions, promoting renewal of the epidermis, stimulating hair regrowth or delaying hair loss
DE4113346A1 (de) * 1991-04-24 1992-10-29 Lang Erich Zubereitung zur kraeftigung und regeneration des haarwuchses
WO1993022773A1 (en) * 1992-05-04 1993-11-11 Berliner David L Process for absorbing ultraviolet radiation using dispersed melanin
US5641509A (en) * 1992-06-26 1997-06-24 Lancaster Group Ag Preparation for topical use
FR2694768B1 (fr) * 1992-07-30 1994-12-23 Pasteur Institut Séquences d'oligonucléotides pour la détection spécifique de mollicutes par amplication de gènes conservés.
US5302389A (en) * 1992-08-17 1994-04-12 Board Of Regents, The University Of Texas System Method for treating UV-induced suppression of contact hypersensitivity by administration of T4 endonuclease
ATE209887T1 (de) * 1993-04-02 2001-12-15 Anticancer Inc Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel

Also Published As

Publication number Publication date
JPH08511510A (ja) 1996-12-03
US5965157A (en) 1999-10-12
DE69429337T3 (de) 2012-08-30
EP0692972A1 (de) 1996-01-24
US6261596B1 (en) 2001-07-17
EP0692972B2 (de) 2012-03-21
CA2159626A1 (en) 1994-10-13
JP2950520B2 (ja) 1999-09-20
CA2159626C (en) 2001-10-02
EP0692972B1 (de) 2001-12-05
AU6554594A (en) 1994-10-24
ATE209887T1 (de) 2001-12-15
DE69429337D1 (de) 2002-01-17
WO1994022468A1 (en) 1994-10-13
US5753263A (en) 1998-05-19
US6224901B1 (en) 2001-05-01
US5914126A (en) 1999-06-22
EP0692972A4 (de) 1998-05-06

Similar Documents

Publication Publication Date Title
DE69429337T2 (de) Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel
DE69837274D1 (de) Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten
DE59611371D1 (de) Verfahren zur Herstellung von Erythropoietin frei von tierischen Proteinen
US8946402B2 (en) Inhibition of hairless protein mRNA
ATE345682T1 (de) In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
BR0108959A (pt) Composições de polox‰mero ou poloxamina melhoradas para distribuição de ácido nucléico
ES2113669T3 (es) Estimulacion del bronceado mediante fragmentos de adn.
NO921875L (no) Metallpeptidpreparater og fremgangsmaater for aa stimulere haarvekst
US20060270621A1 (en) Inhibition of hair growth with RNAi targeting desmoglein 4 and nude mRNAs
HK1032753A1 (en) Vaccination by topical application of genetic vectors
ATE239498T1 (de) Entzündungshemmende zusammensetzung
DE3580531D1 (de) Verfahren zur herstellung lagerstabiler waessriger praeparate von anionischen farbstoffen.
MXPA00006306A (es) Compuestos del canal de ion del cerebro o corazon, regulados por nucleotidos ciclicos y usos de los mismos.
BR9811014A (pt) "região concentrada reguladora de gene especìfica para semente precoce"
PT1072251E (pt) Preparacoes cosmeticas contendo esteres de n-acilaminoacidos
ATE309370T1 (de) Retinoid-metabolisierendes protein
ATE336992T1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz- erkrankungen
WO2000008157A3 (en) Human anion transporter genes atnov
ATE254171T1 (de) Gentherapeutisches verfahren unter verwendung von dna-vektoren ohne selektionsmarker-gen
FR2766190B1 (fr) Nouveaux peptides et polypeptides utiles dans la regeneration du systeme nerveux
HUP0402327A2 (hu) Inzulinszerű növekedési faktort kötő 5-ös fehérje expressziójának antiszensz módosítása
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
DE69801009T2 (de) Zusammensetzung zum Färben, die eine Laccase enthält, und Verfahren zum Färben von Keratinfasern unter Verwendung dieser Zusammensetzung
BR9002240A (pt) Processo para a preparacao de uma composicao conservada apropriada para aplicacao topica a pele e composicao
DE60032143D1 (de) Verwendung von eif4e-bindungsreagenzien in der therapie

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: KRAMER - BARSKE - SCHMIDTCHEN, 81245 MUENCHEN

R102 Epo decision maintaining patent in amended form now final

Ref document number: 692972

Country of ref document: EP